Literature DB >> 6548584

Evidence for impaired hepatic vitamin K1 metabolism in patients treated with N-methyl-thiotetrazole cephalosporins.

H Bechtold, K Andrassy, E Jähnchen, J Koderisch, H Koderisch, L S Weilemann, H G Sonntag, E Ritz.   

Abstract

In 8 patients on no oral intake and with parenteral alimentation, administration of cephalosporins with N-methyl-thiotetrazole side chain (moxalactam, cefamandole), was associated with prolongation of prothrombin time, appearance in the circulation of descarboxy-prothrombin (counter immunoelectrophoresis and echis carinatus assay) and diminution of protein C. Acute administration of 10 mg vitamin K1 was followed by the transient appearance of vitamin K1 2,3-epoxide, indicating an impaired hepatocellular regeneration of vitamin K1 from the epoxide. Impaired hepatic vitamin K1 metabolism, tentatively ascribed to the N-methyl-thiotetrazole group, is one (but possibly not the only) cause of bleeding complications and depression of vitamin K1-dependent procoagulants in patients treated with the new class of cephalosporins.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6548584

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  21 in total

1.  PIVKA-II concentrations in patients with cystic fibrosis.

Authors:  E A Cornelissen; A F van Lieburg; C G van Oostrom; L Monnens
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

Review 2.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Alteration of hemostasis associated with cefoperazone treatment.

Authors:  K Andrassy; J Koderisch; S Fritz; H Bechtold; H Sonntag
Journal:  Infection       Date:  1986 Jan-Feb       Impact factor: 3.553

4.  Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.

Authors:  I J Mackie; K Walshe; H Cohen; P McCarthy; M Shearer; S D Scott; S J Karran; S J Machin
Journal:  J Clin Pathol       Date:  1986-11       Impact factor: 3.411

5.  Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.

Authors:  R R Sieradzan; W A Bottner; M J Fasco; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

6.  Tolerance in patients with terminal renal insufficiency of high doses of cefotaxime.

Authors:  D Höffler; T Wittgens; C Piper
Journal:  Infection       Date:  1985       Impact factor: 3.553

Review 7.  Clinically significant drug interactions with the oral anticoagulants.

Authors:  M D Freedman; A G Olatidoye
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

8.  Pharmacokinetics and hemostasis following administration of a new, injectable oxacephem (6315-S, flomoxef) in volunteers and in patients with renal insufficiency.

Authors:  K Andrassy; J Koderisch; K Gorges; H Sonntag; K Hirauchi
Journal:  Infection       Date:  1991       Impact factor: 3.553

9.  Effect of flomoxef on blood coagulation and alcohol metabolism.

Authors:  K Uchida; T Matsubara
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 10.  Safety profile of cefodizime.

Authors:  K Andrassy
Journal:  Infection       Date:  1992       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.